EG434402 Inhibitors
EG434402 inhibitors are a class of chemical compounds specifically designed to inhibit the activity of the EG434402 molecule, which is likely involved in crucial regulatory pathways within cells. EG434402 is thought to play a role in cellular processes such as protein regulation, enzymatic activity, or signal transduction, making it an important component in maintaining cellular function and balance. By inhibiting EG434402, these compounds interfere with its natural interactions or catalytic activities, thereby altering the pathways and processes it influences. The study of EG434402 inhibitors allows researchers to investigate the precise role of this molecule in various cellular functions and understand how its modulation affects cellular behavior, particularly in contexts like protein turnover or intracellular communication.
Structurally, EG434402 inhibitors are typically designed to interact with key functional domains of the EG434402 molecule, such as its active site or allosteric sites that control its activity. These inhibitors can block the interaction between EG434402 and its substrates or binding partners through competitive inhibition, where they occupy the active site, or through non-competitive inhibition, where they bind to regulatory sites and induce conformational changes that reduce the molecule's effectiveness. The inhibition of EG434402 allows researchers to explore how its activity regulates downstream signaling pathways, protein modifications, or enzymatic reactions. By studying the effects of EG434402 inhibitors, scientists gain valuable insights into the role this molecule plays in orchestrating complex biochemical networks, contributing to the broader understanding of cellular regulation and the molecular mechanisms that ensure proper cellular function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Phosphoinositide 3-kinase (PI3K) inhibitor, affecting PI3K/Akt pathway. Suppresses Gm5617 indirectly by disrupting downstream signaling, impacting nuclear translocation, and altering expression levels through PI3K inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAP kinase inhibitor disrupting the p38 MAPK signaling pathway. Indirectly impacts Gm5617 by interfering with signaling cascades, leading to altered nuclear activity. Inhibits the phosphorylation events that regulate Gm5617 function in the nucleus. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting the PI3K/Akt pathway. Modulates Gm5617 indirectly by impeding PI3K-mediated signaling, resulting in altered nuclear localization and modified expression levels. Influences downstream effectors and disrupts the regulatory network of Gm5617. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor disrupting the JNK signaling pathway. Indirectly influences Gm5617 by altering the JNK cascade, leading to modified nuclear translocation and expression levels. Impacts downstream regulators, contributing to the inhibition of Gm5617 function within the nucleus. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor targeting the MAPK pathway. Indirectly modulates Gm5617 activity by disrupting the MAPK cascade, resulting in altered nuclear localization and modified expression levels. Influences downstream effectors, contributing to the inhibition of Gm5617 in the nucleus. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor affecting the mTOR signaling pathway. Modulates Gm5617 indirectly by disrupting mTOR-mediated signaling, leading to altered nuclear translocation and modified expression levels. Influences downstream effectors, contributing to the inhibition of Gm5617 in the nucleus. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor targeting the MAPK pathway. Indirectly modulates Gm5617 activity by disrupting the MAPK cascade, leading to altered nuclear localization and modified expression levels. Influences downstream effectors, contributing to the inhibition of Gm5617 in the nucleus. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor disrupting TGF-β signaling. Impacts Gm5617 indirectly by interfering with TGF-β-mediated pathways, resulting in altered nuclear translocation and expression levels. Influences downstream effectors, contributing to the inhibition of Gm5617 in the nucleus. | ||||||